- Home
- PCVX vs BLLN Comparison
PCVX vs BLLN Comparison
Compare PCVX & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PCVX | BLLN |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.0B |
| IPO Year | 2020 | 2025 |
Fundamental Metrics
Financial Performance| Metric | PCVX | BLLN |
|---|---|---|
| Price | $46.76 | $112.80 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | $101.67 | ★ $138.67 |
| AVG Volume (30 Days) | ★ 1.5M | 203.3K |
| Earning Date | 11-04-2025 | 12-09-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $209,032,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 112.72 |
| 52 Week Low | $27.66 | $88.00 |
| 52 Week High | $94.60 | $138.70 |
Technical Indicators
Market Signals| Indicator | PCVX | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 51.97 | N/A |
| Support Level | $43.78 | N/A |
| Resistance Level | $48.11 | N/A |
| Average True Range (ATR) | 1.99 | 0.00 |
| MACD | -0.49 | 0.00 |
| Stochastic Oscillator | 42.99 | 0.00 |
Price Performance
Historical ComparisonAbout PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
About BLLN BillionToOne Inc.
BillionToOne Inc is a precision diagnostics company revolutionizing molecular testing with its patented Quantitative Counting Templates (QCT) platform. This technology enables ultrasensitive, single-molecule DNA quantification, making genetic testing more accurate, affordable, and accessible. The company serves prenatal screening and oncology markets with non-invasive tests that detect fetal genetic risks and monitor cancer therapy response.